BioMarin Pharmaceutical Inc. (BMRN)

Wie das Geld verdient wird

Revenue comes from chronic-use drugs administered for a patient's lifetime, mostly billed to insurers and national health systems with whom BioMarin negotiates pricing and reimbursement market by market. Voxzogo, its newest and fastest-growing therapy for a rare bone-growth disorder, has become the single largest product; a group of five older drugs the company calls Enzyme Therapies still supplies the majority of revenue from established treatments with long track records.

Umsatz nach Segment

Patents, orphan-drug exclusivity and the sheer difficulty of developing a rival treatment for a disease affecting only a few thousand patients worldwide give BioMarin years of largely uncontested pricing once a drug is approved. The advantage erodes over time, though: Kuvan lost most of its revenue to generic competition once its exclusivity expired, showing the protection is temporary rather than permanent.

Demand is driven by diagnosed patients needing lifelong treatment for a genetic condition, not by economic conditions or seasonal buying patterns, which makes volumes relatively stable through a downturn. The bigger swing factor is reimbursement: a health system or insurer narrowing what it will pay for a given therapy can reduce revenue even when patient need is unchanged.

Wichtigste Risiken

• Patent and exclusivity expiration — Loss of patent protection or orphan-drug exclusivity opens the door to generic or biosimilar competition, as already happened with Kuvan, directly reducing revenue on the affected product.
• Pricing and reimbursement pressure — High per-patient treatment costs depend on continued coverage from insurers and national health systems; tightening reimbursement or government price controls can reduce revenue even without new competition.
• Rare-disease competition — A crowded field of new entrants developing rival gene and enzyme therapies for the same small patient populations could erode BioMarin's largely uncontested position in specific diseases.
• Concentration in a narrow product set — A large share of revenue rests on a handful of therapies, Voxzogo and the Enzyme Therapies group; a safety issue, manufacturing problem or loss of exclusivity on any one of them has an outsized effect on total revenue.

BioMarin sells largely to specialty distributors, health systems and government payers across many countries rather than to a small number of large commercial customers, and does not disclose a concentrated buyer as a material risk.